We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.

Pipeline Chart

* As of Oct. 2022

Pipeline Chart

3 ADCs

  • Trastuzumab deruxtecan (T-DXd)
  • Patritumab deruxtecan (HER3-DXd)
  • Datopotamab deruxtecan (Dato-DXd)

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer

  • : Project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
  • : Breakthrough designation (US)
  • : Orphan drug designation (JP)

Phase 1

  • (US/EU/Asia) HER2+ BC 2L~/ 1L
    DESTINY-Breast07
  • (US/EU/Asia) HER2 low BC
    Chemo naive/post chemo
    DESTINY-Breast08
  • (JP/US/EU/Asia) HER2+ GC combo, 2L~/1L
    DESTINY-Gastric03
  • (EU/Asia) HER2+ NSCLC
    (durvalumab combo) 1L
    DESTINY-Lung03
  • (US/EU) BC, bladder (nivolumab combo)
  • (US/EU) BC, NSCLC
    (pembrolizumab combo)
  • (US/EU/Asia) Solid tumors
    (AZD5305 combo)
    PETRA
  • (JP/US) NSCLC, TNBC, HR+
    BC, SCLC, GC, urothelial,
    esophageal, prostate, etc.
    TROPION-PanTumor01
  • (CN) NSCLC, TNBC
    TROPION-PanTumor02
  • (JP/US/EU/Asia) NSCLC
    (pembrolizumab combo)
    TROPION-Lung02
  • (JP/US/EU) NSCLC
    (durvalumab combo)
    TROPION-Lung04
  • (JP/US/EU/Asia) Solid tumors
    (AZD5305 combo)
    PETRA
  • (JP/US/EU/Asia) NSCLC
  • (JP/US) EGFR mutant NSCLC
    (osimertinib combo)
  • (JP/US) HER3+ BC

Phase 2

  • (US/EU/Asia) TNBC
    (durvalumab combo)
    BEGONIA
  • (CN) HER2+ GC 3L
    DESTINY-Gastric06
  • (JP/US/EU) HER2+ or HER2 mutant NSCLC 2L~
    DESTINY-Lung01
  • (JP/US/EU/Asia) HER2 mutant NSCLC 2L∼
    DESTINY-Lung02
  • (CN) HER2 mutant NSCLC 2L∼
    DESTINY-Lung05
  • (US/EU/Asia) NSCLC
    (durvalumab combo) 2L∼
    HUDSON
  • (JP/US/EU) HER2+ CRC 3L
    DESTINY-CRC01
  • (JP/US/EU/Asia) HER2+ CRC 3L
    DESTINY-CRC02
  • (JP/US/EU/Asia)
    HER2 mutant tumor
    DESTINY-PanTumor01
  • (US/EU/Asia)
    HER2 expressing tumor
    DESTINY-PanTumor02
  • (JP/US/EU/Asia) endometrial, ovarian, prostate cancer, GC, CRC combo
    TROPION-PanTumor03
  • (JP/US/EU/Asia) NSCLC
    (w/ actionable mutation)
    TROPION-Lung05
  • (US/EU/Asia) TNBC
    (durvalumab combo)
    BEGONIA
  • (JP/US/EU/Asia) EGFR mutated NSCLC 2L
    (osimertinib combo)
    ORCHARD
  • (JP/US/EU/Asia)
    EGFR mutant NSCLC 3L
    HERTHENA-Lung01

Phase 3

  • (JP/US/EU/Asia) HER2+ BC 3L
    DESTINY-Breast02
  • (JP/US/EU/Asia) HER2+ BC
    adjuvant*
    DESTINY-Breast05
  • (JP/US/EU/Asia) HER2 low BC
    chemo naive
    DESTINY-Breast06
  • (JP/US/EU/Asia) HER2+ BC 1L
    DESTINY-Breast09
  • (JP/US/EU/Asia) HER2+ BC
    neoadjuvant
    DESTINY-Breast11
  • (JP/EU/Asia) HER2+ GC 2L
    DESTINY-Gastric04
  • (JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L
    DESTINY-Lung04
  • (JP/US/EU/Asia) NSCLC 2/3L
    TROPION-Lung01
  • (JP/US/EU/Asia) NSCLC
    (w/o actionable mutation, pembro combo) 1L
    TROPION-Lung07 (in prep.)
  • (JP/US/EU/Asia) NSCLC
    (w/o actionable mutation, pembro combo) 1L
    TROPION-Lung08
  • (JP/US/EU/Asia) HR+ BC 2/3L
    TROPION-Breast01
  • (JP/US/EU/Asia) TNBC 1L
    TROPION-Breast02
  • (JP/US/EU/Asia) EGFR mutated
    NSCLC 2L
    HERTHENA-Lung02


*DESTINY-Breast05: adjuvant therapy for patients with HER2 positive early breast cancer with high risk

Submitted

  • (JP/China) HER2+ BC 2L
    DESTINY-Breast03
  • (EU) HER2+ GC 2L
    DESTINY-Gastric02
  • (JP/EU/China) HER2 low BC
    post chemo
    DESTINY-Breast04

Alpha

  • Oncology
  • Specialty Medicines
  • Vaccine

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressive, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma

  • : Project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
  • : SAKIGAKE Designation (JP)
  • : Orphan drug designation (JP/US/EU)

Phase 1

  • Ifinatamab deruxtecan (I-Dxd, DS-7300) (JP/US)
    B7-H3-directed ADC
    ESCC, CRPC, squamous NSCLC, etc.
  • DS-6000 (JP/US)
    CDH6-directed ADC
    Renal cell carcinoma, ovarian cancer
  • DS-1055 (JP/US)
    Anti-GARP antibody
    Solid tumors
  • DS-6016 (JP)
    Anti-ALK2 antibody
    FOP
  • DS-7011 (US)
    Anti-TLR7 antibody
    Systemic lupus erythematosus
  • DS-2325 (US)
    KLK5 inhibitor
    Netherton syndrome
  • PLX2853 (US)
    BET inhibitor
    AML
  • PLX2853 (US)
    BET inhibitor
    Solid tumor
  • PLX2853 (US)
    BET inhibitor
    Gynecologic neoplasms, ovarian cancer
  • PLX2853 (US)
    BET inhibitor
    Prostate cancer
  • DS-1594 (US)
    Menin-MLL binding inhibitor
    AML, ALL
  • DS-9606 (US/EU)
    Target undisclosed ADC
    Solid tumors

Phase 2

  • Valemetostat (DS-3201) (JP/US/EU/Asia)
    EZH1/2 inhibitor
    PTCL
  • Valemetostat (DS-3201) (EU)
    EZH1/2 inhibitor
    BCL
  • DS-1001 (JP)
    Mutant IDH1 inhibitor
    Glioma
  • Ifinatamab deruxtecan (I-Dxd, DS-7300) (JP/US/EU/Asia)
    B7-H3-directed ADC
    ES-SCLC
  • DS-5141 (JP)
    ENA oligonucleotide DMD
  • DS-1211 (US/EU)
    TNAP inhibitor
    Pseudoxanthoma elasticum (in prep.)
  • DS-5670 (JP)
    COVID-19 mRNA vaccine
    COVID-19 (primary vaccination, 5 to 11 aged children) (in prep.)
  • VN-0200 (JP)
    RS virus vaccine
    RS virus infection

Phase 3

  • Pexidartinib (JP/Asia)
    CSF-1/KIT/FLT3 inhibitor
    Tenosynovial giant cell tumor
  • Esaxerenone (JP)
    MR blocker
    Diabetic nephropathy
  • VN-0102/JVC-001 (JP)
    Measles mumps rubella
    combined vaccine
  • DS-5670 (JP)
    COVID-19 mRNA vaccine
    COVID-19 (booster vaccination)
  • DS-5670 (JP)
    COVID-19 mRNA vaccine
    COVID-19 (primary vaccination, adults)
  • DS-5670 (JP)
    COVID-19 mRNA vaccine
    COVID-19 (primary vaccination, 12 to 17 aged children) (in prep.)

Submitted

  • Quizartinib (JP/US/EU)
    FLT3 inhibitor
    AML 1L
  • VN-0107/MEDI3250 (JP)
    Live attenuated influenza vaccine nasal spray